Authors: Matthay ZA, Fields AT, Nunez-Garcia B, Park JJ, Jones C, Leligdowicz A, Hendrickson CM, Callcut RA, Matthay MA, Kornblith LZ
Authors: Klompas M, Branson R, Cawcutt K, Crist M, Eichenwald EC, Greene LR, Lee G, Maragakis LL, Powell K, Priebe GP, Speck K, Yokoe DS, Berenholtz SM
Authors: Shrestha I, Ming K, Jimenez V, Wendelborn J, Vazquez A, Steward W, Scott HM, Saberi P
Volume 13 of Issue 1 | Nature communications
Authors: Zeng L, Liu Y, Nguyenla XH, Abbott TR, Han M, Zhu Y, Chemparathy A, Lin X, Chen X, Wang H, Rane DA, Spatz JM, Jain S, Rustagi A, Pinsky B, Zepeda AE, Kadina AP, Walker JA, Holden K, Temperton N, Cochran JR, Barron AE, Connolly MD, Blish CA, Lewis DB, Stanley SA, La Russa MF, Qi LS
A major challenge in coronavirus vaccination and treatment is to counteract rapid viral evolution and mutations. Here we demonstrate that CRISPR-Cas13d offers a broad-spectrum antiviral (BSA) to inhibit many SARS-CoV-2 variants and diverse human coronavirus strains with >99% reduction of the viral titer. We show that Cas13d-mediated coronavirus inhibition is dependent on the crRNA cellular spatial colocalization with Cas13d and target viral RNA. Cas13d can significantly enhance the therapeutic effects of diverse small molecule drugs against coronaviruses for prophylaxis or treatment purposes, and the best combination reduced viral titer by over four orders of magnitude. Using lipid nanoparticle-mediated RNA delivery, we demonstrate that the Cas13d system can effectively treat infection from multiple variants of coronavirus, including Omicron SARS-CoV-2, in human primary airway epithelium air-liquid interface (ALI) cultures. Our study establishes CRISPR-Cas13 as a BSA which is highly complementary to existing vaccination and antiviral treatment strategies.
View on PubMed
Journal of the Society for Cardiovascular Angiography & Interventions
Authors: Kavinsky CJ, Szerlip M, Goldsweig AM, Amin Z, Boudoulas KD, Carroll JD, Coylewright M, Elmariah S, MacDonald LA, Shah AP, Spies C, Tobis JM, Messé SR, Senerth E, Falck-Ytter Y, Babatunde I, Morgan RL
Authors: Alexander SM, Agaba A, Campbell JI, Nambogo N, Camlin CS, Johnson M, Dorsey G, Olson KR, Bangsberg DR, Carroll RW, Santorino D, Krezanoski PJ
Authors: Kalra M, Henry E, McCann K, Karuturi MS, Bustamante Alvarez JG, Parkes A, Wesolowski R, Wei M, Mougalian SS, Durm G, Qin A, Schonewolf C, Trivedi M, Armaghani AJ, Wilson FH, Iams WT, Turk AA, Vikas P, Cecchini M, Lubner S, Pathak P, Spencer K, Koshkin VS, Labriola MK, Marshall CH, Beckermann KE, theMednet.org NCI-CCC Tumor Board Program Collaborative Group, Sharifi MN, Bejjani AC, Hotchandani V, Housri S, Housri N
Volume 16 of Issue 5 | PLoS neglected tropical diseases
Authors: Bratcher A, Hoff NA, Doshi RH, Gadoth A, Halbrook M, Mukadi P, Musene K, Ilunga-Kebela B, Spencer D, Bramble MS, McIlwain D, Kelly JD, Mukadi D, Kingebeni PM, Ahuka S, Okitolonda-Wemakoy E, -Jacques Muyembe-Tamfum J, Rimoin AW
[This corrects the article DOI: 10.1371/journal.pntd.0009566.].
View on PubMed
Journal of Asian health
Authors: Ahmed N, De Silva D, Kanaya AM, Kandula NR
Leukemia & lymphoma
Authors: Maeng CV, Christiansen CF, Liu KD, Kamper P, Christensen S, Medeiros BC, ?stg?rd LSG